Document is current
Any future updates will be listed below
-
Authors
Huang, Tianwen
He, Yangyang
Cheng, Ruijuan
Zhang, Qiuping
Zhong, Xiang
Hashimoto, Kenji https://orcid.org/0000-0002-8892-0439
Liu, Yi
Pu, Yaoyu
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82101616)
- License Information
-
More Information
Article History
Received: 17 May 2024
Revised: 25 October 2024
Accepted: 30 October 2024
First Online: 9 November 2024
Competing interests
: KH is the inventor of filed patent applications on “The use of R-Ketamine in the treatment of psychiatric diseases”, “(S)-norketamine and salt thereof as pharmaceutical”, “R-Ketamine and derivative thereof as prophylactic or therapeutic agent for neurodegeneration disease or recognition function disorder”, “Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases”, and “R-Ketamine and its derivatives as a preventive or therapeutic agent for a neurodevelopmental disorder” by the Chiba University. KH has also received speakers’ honoraria, consultant fee, or research support from Otsuka. The other authors declare no competing interest.
: The experimental protocol of this study was approved by the Institutional Animal Care and Use Committee of the West China Hospital, Sichuan University (Permission Number 20230807003).
